Patents by Inventor Peter A. Seubert

Peter A. Seubert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210032319
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: July 20, 2020
    Publication date: February 4, 2021
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter SEUBERT, Philip James DOLAN, III, Yue LIU, Robin BARBOUR
  • Publication number: 20210008185
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 20, 2020
    Publication date: January 14, 2021
    Applicant: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Dale B. SCHENK, Peter A. SEUBERT, Jonathan WALL, José SALDANHA
  • Patent number: 10752679
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: August 25, 2020
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Publication number: 20200123239
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: October 29, 2019
    Publication date: April 23, 2020
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Patent number: 10501531
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: December 10, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Publication number: 20190322728
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2017
    Publication date: October 24, 2019
    Inventors: Peter SEUBERT, Philip James DOLAN, III, Yue LIU, Robin BARBOUR
  • Publication number: 20180360934
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 20, 2018
    Applicants: PROTHENA THERAPEUTICS LIMITED, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: DALE B. SCHENK, PETER A. SEUBERT, JONATHAN WALL, JOSÉ SALDANHA
  • Publication number: 20170081396
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: May 20, 2016
    Publication date: March 23, 2017
    Applicants: PROTHENA THERAPEUTICS LIMITED, UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: DALE B. SCHENK, PETER A. SEUBERT, JONATHAN WALL, JOSÉ SALDANHA
  • Publication number: 20160031976
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 4, 2016
    Applicant: Prothena Biosciences Limited
    Inventors: Peter Seubert, Philip James Dolan, III, Yue Liu, Robin Barbour
  • Publication number: 20150158937
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: June 25, 2014
    Publication date: June 11, 2015
    Applicant: ONCLAVE THERAPEUTICS LIMITED
    Inventors: Dale B. SCHENK, Peter A. SEUBERT, José SALDANHA
  • Patent number: 8791243
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Grant
    Filed: December 29, 2008
    Date of Patent: July 29, 2014
    Assignee: Onclave Therapeutics Limited
    Inventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall, Jose Saldanha
  • Publication number: 20140134103
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: December 6, 2013
    Publication date: May 15, 2014
    Applicants: University of Tennessee Research Foundation, Elan Pharmaceuticals, Inc.
    Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José Saldanha
  • Patent number: 8636981
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: January 28, 2014
    Assignee: Onclave Therapeutics
    Inventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall
  • Patent number: 8404815
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: March 26, 2013
    Assignee: Onclave Therapeutics
    Inventors: Dale B. Schenk, Peter A. Seubert
  • Patent number: 8357781
    Abstract: The application provides novel neuroactive fragments of human amyloid precursor protein (APP). The fragments include sequence from the A? region of APP but also extend upstream. The fragments are soluble in aqueous solution most bands are about 10 kDa and above and do not correspond with the expected molecular weight of a dimer or trimer. The fragments and subfragments thereof can be used as immunogens in methods of immunotherapy to treat Alzheimer's and other amyloidogenic diseases characterized by deposits of A? in the brain. Antibodies to the part of the fragment upstream from APP or the interface between A? and the upstream sequence can also be used in such therapeutic method. The fragments are also useful as markers, which can be detected for diagnosis or prognosis of disease or for screening agents.
    Type: Grant
    Filed: June 1, 2007
    Date of Patent: January 22, 2013
    Assignee: Janssen Alzheimer Immunotherapy
    Inventors: Kelly Johnson-Wood, Peter Seubert, Thierry Bussiere
  • Publication number: 20120321555
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: April 30, 2012
    Publication date: December 20, 2012
    Applicants: University of Tennessee Research Foundation, Elan Pharmaceuticals, Inc.
    Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José W. Saldanha
  • Patent number: 8268973
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: September 18, 2012
    Assignee: Onclave Therapeutics
    Inventors: Dale B. Schenk, Peter A. Seubert, José Saldanha
  • Publication number: 20120189624
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: December 7, 2011
    Publication date: July 26, 2012
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall, José W. Saldanha
  • Publication number: 20120039878
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: July 20, 2011
    Publication date: February 16, 2012
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Dale B. Schenk, Peter A. Seubert, Jonathan Wall, José W. Saldanha
  • Publication number: 20110224408
    Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
    Type: Application
    Filed: February 22, 2011
    Publication date: September 15, 2011
    Applicants: ELAN PHARMACEUTICALS, INC., UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION
    Inventors: Dale B. SCHENK, Peter A. Seubert, Jonathan Wall, José W. Saldanha